DBV Technologies S.A. (DBVT)
Automate Your Wheel Strategy on DBVT
With Tiblio's Option Bot, you can configure your own wheel strategy including DBVT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DBVT
- Rev/Share 0.0113
- Book/Share 0.028
- PB 70.3642
- Debt/Equity 0.0
- CurrentRatio 0.7218
- ROIC -8.5757
- MktCap 269335415.0
- FreeCF/Share -0.8815
- PFCF -2.9775
- PE -1.7787
- Debt/Assets 0.0
- DivYield 0
- ROE -2.6846
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | DBVT | Goldman | -- | Sell | -- | $7.25 | May 29, 2025 |
News
Are Medical Stocks Lagging DBV Technologies (DBVT) This Year?
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how DBV Technologies S.A. (DBVT) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Read More
Are You Looking for a Top Momentum Pick? Why DBV Technologies S.A.
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Does DBV Technologies S.A. (DBVT) have what it takes to be a top stock pick for momentum investors?
Read More
DBV Technologies (DBVT) Is a Great Choice for 'Trend' Investors, Here's Why
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
DBV Technologies (DBVT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
Here's Why Momentum in DBV Technologies (DBVT) Should Keep going
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
DBV Technologies (DBVT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
DBV Technologies ADRs Rise After Up to $306.9M in New Financing
Published: March 28, 2025 by: Market Watch
Sentiment: Positive
American depositary receipts of DBV Technologies gained after the company reported new financing of up to $306.9 million.
Read More
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Châtillon, France, March 24, 2025 DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for Biologics License Application (BLA) for Viaskin® Peanut Patch in 4 – 7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, and Reports 2024 Unaudited Financial Results 1 COMFORT Children supplemental safety study in children 4 – 7-years-old no longer required FDA confirms safety exposure data generated from VITESSE Phase 3 clinical study and VITESSE Open-Label Extension (OLE) are sufficient to support a Biologics License Application (BLA) for Viaskin peanut patch in children 4 – 7-years-old VITESSE topline results on-track for …
Read More
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Châtillon, France, February 25, 2025 DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization (AAAAI/WAO) Joint Congress, February 28-March 3, 2025, in San Diego, CA. An oral abstract presentation by Dr. David Fleischer, FAAAAI, FACAAI, Professor of Pediatrics at Children's Hospital Colorado, will describe Month 60 (M60), end-of-study efficacy and safety results from PEOPLE (the open-label extension of the 12-month, double-blind placebo-controlled, Phase 3 …
Read More
About DBV Technologies S.A. (DBVT)
- IPO Date 2014-10-22
- Website https://www.dbv-technologies.com
- Industry Biotechnology
- CEO Mr. Daniel Tassé
- Employees 106